Vir Biotech Shares Rise on Positive Data for Cancer Treatments

Dow Jones01-08 23:14

By Chris Wack

Vir Biotechnology shares were up 67% to $13.15 after the company reported encouraging initial Phase 1 data for its dual-masked T-cell engagers, VIR-5818 and VIR-5500.

The clinical-stage biopharmaceutical company said VIR-5818 targets HER2-expressing solid tumors, showing tumor shrinkage in 50% of heavily pretreated participants, with no significant adverse events.

VIR-5818 is being tested alone and with pembrolizumab across various cancers, including breast and colorectal cancer.

The San Francisco company said VIR-5500, for metastatic castration-resistant prostate cancer, has shown PSA reductions in all participants.

Both drugs exhibit favorable safety profiles with no dose-limiting cytokine release syndrome or toxicities, suggesting effective tumor-specific activation due to the PRO-XTEN masking technology. Both studies continue dose escalation, with no maximum tolerated dose yet determined, and are exploring less frequent dosing due to prolonged drug half-life.

Write to Chris Wack at chris.wack@wsj.com

(END) Dow Jones Newswires

January 08, 2025 10:14 ET (15:14 GMT)

Copyright (c) 2025 Dow Jones & Company, Inc.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2501776447?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-01-08 23:14","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2501776447","market":"other","top_or_hot":-1,"title":"Vir Biotech Shares Rise on Positive Data for Cancer Treatments","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<pre>\n \n</pre>\n<p>\n  By Chris Wack \n</p>\n<pre>\n \n</pre>\n<p>\n  Vir Biotechnology shares were up 67% to $13.15 after the company reported encouraging initial Phase 1 data for its dual-masked T-cell engagers, VIR-5818 and VIR-5500. \n</p>\n<p>\n  The clinical-stage biopharmaceutical company said VIR-5818 targets HER2-expressing solid tumors, showing tumor shrinkage in 50% of heavily pretreated participants, with no significant adverse events. \n</p>\n<p>\n  VIR-5818 is being tested alone and with pembrolizumab across various cancers, including breast and colorectal cancer. \n</p>\n<p>\n  The San Francisco company said VIR-5500, for metastatic castration-resistant prostate cancer, has shown PSA reductions in all participants. \n</p>\n<p>\n  Both drugs exhibit favorable safety profiles with no dose-limiting cytokine release syndrome or toxicities, suggesting effective tumor-specific activation due to the PRO-XTEN masking technology. Both studies continue dose escalation, with no maximum tolerated dose yet determined, and are exploring less frequent dosing due to prolonged drug half-life. \n</p>\n<pre>\n \n</pre>\n<p>\n  Write to Chris Wack at chris.wack@wsj.com \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  January 08, 2025 10:14 ET (15:14 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Vir Biotech Shares Rise on Positive Data for Cancer Treatments</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nVir Biotech Shares Rise on Positive Data for Cancer Treatments\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-01-08 23:14 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://dowjonesnews.com/newdjn/logon.aspx?AL=N><strong>Dow Jones</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>By Chris Wack \n\n\n \n\n\n  Vir Biotechnology shares were up 67% to $13.15 after the company reported encouraging initial Phase 1 data for its dual-masked T-cell engagers, VIR-5818 and VIR-5500. \n\n\n  The ...</p>\n\n<a href=\"https://dowjonesnews.com/newdjn/logon.aspx?AL=N\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4585","symbol_name":"ETF&股票定投概念","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2501776447","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2501776447","pubTimestamp":1736349240,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Vir Biotechnology shares were up 67% to $13.15 after the company reported encouraging initial Phase 1 data for its dual-masked T-cell engagers, VIR-5818 and VIR-5500.The clinical-stage biopharmaceutical company said VIR-5818 targets HER2-expressing solid tumors, showing tumor shrinkage in 50% of heavily pretreated participants, with no significant adverse events.VIR-5818 is being tested alone and with pembrolizumab across various cancers, including breast and colorectal cancer.The San Francisco company said VIR-5500, for metastatic castration-resistant prostate cancer, has shown PSA reductions in all participants.Both drugs exhibit favorable safety profiles with no dose-limiting cytokine release syndrome or toxicities, suggesting effective tumor-specific activation due to the PRO-XTEN masking technology. Both studies continue dose escalation, with no maximum tolerated dose yet determined, and are exploring less frequent dosing due to prolonged drug half-life.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4585":"ETF&股票定投概念","BK4139":"生物科技","BK4568":"美国抗疫概念","VIR":"Vir Biotechnology, Inc.","BK4535":"淡马锡持仓"},"translate_title":"Vir Biotech股价因癌症治疗的积极数据而上涨","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"VIR":0.9},"content_text":"By Chris Wack \n\n\n \n\n\n  Vir Biotechnology shares were up 67% to $13.15 after the company reported encouraging initial Phase 1 data for its dual-masked T-cell engagers, VIR-5818 and VIR-5500. \n\n\n  The clinical-stage biopharmaceutical company said VIR-5818 targets HER2-expressing solid tumors, showing tumor shrinkage in 50% of heavily pretreated participants, with no significant adverse events. \n\n\n  VIR-5818 is being tested alone and with pembrolizumab across various cancers, including breast and colorectal cancer. \n\n\n  The San Francisco company said VIR-5500, for metastatic castration-resistant prostate cancer, has shown PSA reductions in all participants. \n\n\n  Both drugs exhibit favorable safety profiles with no dose-limiting cytokine release syndrome or toxicities, suggesting effective tumor-specific activation due to the PRO-XTEN masking technology. Both studies continue dose escalation, with no maximum tolerated dose yet determined, and are exploring less frequent dosing due to prolonged drug half-life. \n\n\n \n\n\n  Write to Chris Wack at chris.wack@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  January 08, 2025 10:14 ET (15:14 GMT)\n\n\n  Copyright (c) 2025 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.30.0","shortVersion":"4.30.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2501776447"}